Cerulea Clinical Trials

Science and Research

GALE

A Phase III, Open-Label, Multi-Centre, Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan in Subjects with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD).

Overview

A Phase III, Open-Label, Multi-Centre, Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan in Subjects with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD).

  • Principal Investigator
Professor Robyn Guymer AM

Learn more

View this study on ClinicalTrials.gov

See the ClinicalTrials.gov database listing for more detailed information about this study.